A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : TRAIL / tumor necrosis factor-related apoptosis-inducing ligand

[Related PubMed/MEDLINE]
Total Number of Papers: 3438
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   TRAIL  (>> Co-occurring Abbreviation)
Long Form:   tumor necrosis factor-related apoptosis-inducing ligand
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 ATM kinase regulates tumor immunoreactions in lymphocyte-predominant breast cancer through modulation of NKG2D ligand and TNF cytokines on tumor cells. ATM, FASL, FOXP3, LPBC, MICA, TNBC
2020 Cathepsin K inhibition-induced mitochondrial ROS enhances sensitivity of cancer cells to anti-cancer drugs through USP27x-mediated Bim protein stabilization. Cat K
2020 Death Receptors and Their Ligands in Inflammatory Disease and Cancer. TNF
2020 Everolimus enhances TRAIL-mediated anti-tumor activity of liver resident natural killer cells in mice. EVR
2020 Fas-FasL interaction in cytotoxic T cell-mediated vitiligo: The role of lesional expression of tumor necrosis factor-alpha and interferon-gamma in Fas-mediated melanocyte apoptosis. CTL, FasL, IFN, TNF
2020 Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond. OPG, RANK, RANK
2020 HIF1alpha-mediated TRAIL Expression Regulates Lacrimal Gland Inflammation in Dry Eye Disease. cKO, DED, HIF, LGs
2020 Hyaluronic acid-coated pH sensitive poly (beta-amino ester) nanoparticles for co-delivery of embelin and TRAIL plasmid for triple negative breast cancer treatment. EMB, HA, PEI, TNBC
2020 Inhibition of cyclinB1 Suppressed the Proliferation, Invasion, and Epithelial Mesenchymal Transition of Hepatocellular Carcinoma Cells and Enhanced the Sensitivity to TRAIL-Induced Apoptosis. GEPIA, HCC, qRT-PCR, Sh-cyclinB1
10  2020 Knockdown of Enhancer of Zeste Homolog 2 Affects mRNA Expression of Genes Involved in the Induction of Resistance to Apoptosis in MOLT-4 Cells. EZH2, PRAME
11  2020 Ligand nanovectorization using graphene to target cellular death receptors of cancer cell. DRs
12  2020 Long noncoding RNA TANCR promotes gammadelta T cells activation by regulating TRAIL expression in cis. IPP, lncRNAs
13  2020 Maternal omega3 docosapentaenoic acid inhibits infant allergic dermatitis through TRAIL-expressing plasmacytoid dendritic cells in mice. CHS, DPA, pDCs
14  2020 MicroRNA-181a exerts anti-inflammatory effects via inhibition of the ERK pathway in mice with intervertebral disc degeneration. DHI, ERK, IDD
15  2020 Non-apoptotic TRAIL function modulates NK cell activity during viral infection. LCMV
16  2020 p-Hydroxylcinnamaldehyde from cochinchinamomordica seed reverses resistance to TRAIL in human oesophageal squamous cell carcinoma via the activation of the p38 mitogen-activated protein kinase signalling pathway. CMS, ESCC
17  2020 RANKL triggers resistance to TRAIL-induced cell death in oral squamous cell carcinoma. OSCC, RANKL, RANKL
18  2020 Tannic Acid Promotes TRAIL-Induced Extrinsic Apoptosis by Regulating Mitochondrial ROS in Human Embryonic Carcinoma Cells. EC, ROS, TA
19  2020 Targeting of keloid with TRAIL and TRAIL-R2/DR5. DR5
20  2020 Targeting PP2A inhibits the growth of triple-negative breast cancer cells. PP2A, TNBC
21  2020 TNF-related apoptosis-inducing ligand (TRAIL) promotes trophoblast cell invasion via miR-146a-EGFR/CXCR4 axis: A novel mechanism for preeclampsia? PE
22  2020 TRAIL in oncology: From recombinant TRAIL to nano- and self-targeted TRAIL-based therapies. ---
23  2020 TRAIL receptors are differentially regulated and clinically significant in gallbladder cancer. ELISA, GBC, RT-PCR
24  2020 Tranilast attenuates methotrexate-induced renal and hepatic toxicities: Role of apoptosis-induced tissue proliferation. MTX, TRAN
25  2020 Tumor necrosis factor‑related apoptosis‑inducing ligand as a therapeutic option in urothelial cancer cells with acquired resistance against first‑line chemotherapy. cIAP, Smac, XIAP
26  2020 Vemurafenib may overcome TNF-related apoptosis-inducing ligand (TRAIL) resistance in anaplastic thyroid cancer cells. ATC, TKIs
27  2019 17-Hydroxy Wortmannin Restores TRAIL's Response by Ameliorating Increased Beclin 1 Level and Autophagy Function in TRAIL-Resistant Colon Cancer Cells. 17-HW, BECN1, ECD
28  2019 Accelerated degradation of cFLIPL and sensitization of the TRAIL DISC-mediated apoptotic cascade by pinoresinol, a lignan isolated from Rubia philippinensis. c-FLIPL, DISC
29  2019 Acetylshikonin Sensitizes Hepatocellular Carcinoma Cells to Apoptosis through ROS-Mediated Caspase Activation. ASH, DAPI, HCC, NAC, ROS, TUNEL
30  2019 Adipose tissue-derived mesenchymal stem cells cultured at high density express IFN-beta and TRAIL and suppress the growth of H460 human lung cancer cells. IFN, MSCs
31  2019 Ampelopsin Induces DR5-Mediated Apoptotic Cell Death in EBV-Infected Cells through the p38 Pathway. AMP, EBV, MAPKs
32  2019 Andrographolide Enhances TRAIL-Induced Apoptosis via p53-Mediated Death Receptors Up-Regulation and Suppression of the NF-кB Pathway in Bladder Cancer Cells. ---
33  2019 Antitumor Effect of Periplocin in TRAIL-Resistant gastric cancer cells via upregulation of death receptor through activating ERK1/2-EGR1 pathway. GC
34  2019 Assessing the Functional Relevance of Variants in the IKAROS Family Zinc Finger Protein 1 (IKZF1) in a Cohort of Patients With Primary Immunodeficiency. CVID, HC-PC, IBD, IKZF1
35  2019 Auriculasin sensitizes primary prostate cancer cells to TRAIL-mediated apoptosis through up-regulation of the DR5-dependent pathway. AC, DR5, mTOR, PI3K
36  2019 Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL‑induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species. ROS
37  2019 Autophagy inhibitors regulate TRAIL sensitivity in human malignant cells by targeting the mitochondrial network and calcium dynamics. ---
38  2019 Boosting of Hepatitis B Virus-Specific T Cell Responses After Pegylated-Interferon-alpha-2a Therapy for Hepatitis B e Antigen-Positive Pediatric Patients. HBeAg, HBV, NK, PEG-IFN-alpha
39  2019 Breathing New Life into TRAIL for Breast Cancer Therapy: Co-Delivery of pTRAIL and Complementary siRNAs Using Lipopolymers. BCL2L12, PEI, siRNAs, SOD1
40  2019 c-MYC Drives Breast Cancer Metastasis to the Brain, but Promotes Synthetic Lethality with TRAIL. BrMs
41  2019 Cannabidiol Enhances the Therapeutic Effects of TRAIL by Upregulating DR5 in Colorectal Cancer. CHOP, PERK
42  2019 Cardiac glycoside sensitized hepatocellular carcinoma cells to TRAIL via ROS generation, p38MAPK, mitochondrial transition, and autophagy mediation. CGs, NAC, ROS
43  2019 Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5. DR5
44  2019 Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway. DR5
45  2019 Chrysanthemulide A induces apoptosis through DR5 upregulation via JNK-mediated autophagosome accumulation in human osteosarcoma cells. CA, DR5, JNK, siRNA
46  2019 Circulating Tumor Cells Develop Resistance to TRAIL-Induced Apoptosis Through Autophagic Removal of Death Receptor 5: Evidence from an In Vitro Model. CTCs, DR
47  2019 Co-delivery of TRAIL and siHSP70 using hierarchically modular assembly formulations achieves enhanced TRAIL-resistant cancer therapy. HAase, MMP2
48  2019 Codium fragile F2 sensitize colorectal cancer cells to TRAIL-induced apoptosis via c-FLIP ubiquitination. CE, CRC
49  2019 Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells. DDLPS, DR5, FACS, LPS, PDCs
50  2019 Combined effects of XAF1 and TRAIL on the apoptosis of lung adenocarcinoma cells. MOI, rhTRAIL, XIAP
51  2019 Corrigendum to "Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model" [International Journal of Pharmaceutics 549 (2018) 218-229]. Exo-TRAIL, MSCs
52  2019 Countering TRAIL Resistance in Melanoma. ROS, XIAP
53  2019 CRISPR-mediated upregulation of DR5 and downregulation of cFLIP synergistically sensitize HeLa cells to TRAIL-mediated apoptosis. dCas9
54  2019 Crucial role of reactive oxygen species (ROS) for the proapoptotic effects of indirubin derivative DKP-073 in melanoma cells. ROS
55  2019 Cytomegalovirus Evades TRAIL-Mediated Innate Lymphoid Cell 1 Defenses. CMV, cNK, ILCs, MCMV, SG, TNF, TRAIL-DR
56  2019 Cytotoxicity of Human Hepatic Intrasinusoidal CD56bright Natural Killer Cells against Hepatocellular Carcinoma Cells. FASL, HCC, HI, NK
57  2019 Death receptor 5 contributes to cardiomyocyte hypertrophy through epidermal growth factor receptor transactivation. DR, EGFR
58  2019 Defining characteristics of genital health in South African adolescent girls and young women at high risk for HIV infection. AGYW, IL, MIP
59  2019 Defining rules for cancer cell proliferation in TRAIL stimulation. BIS, PK
60  2019 Delivery of TRAIL-expressing plasmid DNA to cancer cells in vitro and in vivo using aminoglycoside-derived polymers. pEF-GFP, pEF-TRAIL
61  2019 Designing combination therapies with modeling chaperoned machine learning. ---
62  2019 Diallyl disulfide (DADS) boosts TRAIL-Mediated apoptosis in colorectal cancer cells by inhibiting Bcl-2. CRC, DADS
63  2019 Dihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer Cells via TRAIL. ADT
64  2019 Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity toward autologous melanoma cells. HLA, NK, RIG-I
65  2019 Down-regulation of Survivin by BIX-01294 Pretreatment Overcomes Resistance of Hepatocellular Carcinoma Cells to TRAIL. EHMT2, HCC, sg
66  2019 DR4-Ser424 O-GlcNAcylation Promotes Sensitization of TRAIL-Tolerant Persisters and TRAIL-Resistant Cancer Cells to Death. ---
67  2019 Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer. NSCLC
68  2019 Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism. AML, Bcl-2
69  2019 Engineered human mesenchymal stem cells for neuroblastoma therapeutics. MSCs
70  2019 Evaluation of Combination Treatment Effect With TRAIL-secreting Mesenchymal Stem Cells and Compound C Against Glioblastoma. Bcl-2, FLIP, XIAP
71  2019 Exploiting tumor-intrinsic signals to induce mesenchymal stem cell-mediated suicide gene therapy to fight malignant glioma. GBM, MSC
72  2019 Fenofibrate potentiates chemosensitivity to human breast cancer cells by modulating apoptosis via AKT/NF-kappaB pathway. ---
73  2019 Ferroptosis-inducing agents enhance TRAIL-induced apoptosis through upregulation of death receptor 5. DR5, ER, SRF
74  2019 Galbanic acid potentiates TRAIL induced apoptosis in resistant non-small cell lung cancer cells via inhibition of MDR1 and activation of caspases and DR5. Bcl-2, Bcl-xL, DcR1, DR5, GBA, MDR1, NSCLCs, TUNEL, XIAP
75  2019 Gene Expression of Molecules Regulating Apoptotic Pathways in Glioblastoma Multiforme Treated with Umbilical Cord Stem Cell Conditioned Medium. GBM, MSCs, qRT-PCR, UCMSC-CM
76  2019 Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer Models. Bcl-2, JNK, shRNA, XIAP
77  2019 Hematopoietic stem cell gene therapy for brain metastases using myeloid cell-specific gene promoters. BrM, GFP, HSCs
78  2019 Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients. ---
79  2019 Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells. HDAC, HDACi's
80  2019 HIV elite control is associated with reduced TRAILshort expression. PBMCs
81  2019 HNL (Human Neutrophil Lipocalin) and a multimarker approach to the distinction between bacterial and viral infections. HBP, HNL, P-HNL, ROC, TK1
82  2019 Honokiol Enhances TRAIL-Mediated Apoptosis through STAMBPL1-Induced Survivin and c-FLIP Degradation. ---
83  2019 HPV-Mediated Resistance to TNF and TRAIL Is Characterized by Global Alterations in Apoptosis Regulatory Factors, Dysregulation of Death Receptors, and Induction of ROS/RNS. HR-HPV, ROS/RNS, TNF, TNFR1
84  2019 Hsp90 Inhibitor SNX-2112 Enhances TRAIL-Induced Apoptosis of Human Cervical Cancer Cells via the ROS-Mediated JNK-p53-Autophagy-DR5 Pathway. ROS
85  2019 Hydroxychavicol sensitizes imatinib-resistant chronic myelogenous leukemia cells to TRAIL-induced apoptosis by ROS-mediated IAP downregulation. HCH
86  2019 Identification of New DR5 Agonistic Nanobodies and Generation of Multivalent Nanobody Constructs for Cancer Treatment. DR5, Nbs
87  2019 IFN‑beta sensitizes TRAIL‑induced apoptosis by upregulation of death receptor 5 in malignant glioma cells. DR4, TNF
88  2019 Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells. ---
89  2019 Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma. CDK, GBM, PDX
90  2019 Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD. ---
91  2019 In Vitro Effects of Mesenchymal Stem Cells and Various Agents on Apoptosis of Glioblastoma Cells. ADMSCs, GBM, SAHA, XIAP
92  2019 Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy. HSV-TK, MSC
93  2019 Inflammatory bowel disease-associated ubiquitin ligase RNF183 promotes lysosomal degradation of DR5 and TRAIL-induced caspase activation. DR5, DSS, IBD, TNF
94  2019 Insight into the role of TRAIL in liver diseases. HCC
95  2019 Interactions of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) with the Immune System: Implications for Inflammation and Cancer. TNF
96  2019 Interferon beta and Anti-PD-1/PD-L1 Checkpoint Blockade Cooperate in NK Cell-Mediated Killing of Nasopharyngeal Carcinoma Cells. IFN-beta, NK, NPC
97  2019 Invariant NKT Cell-Mediated Modulation of ILC1s as a Tool for Mucosal Immune Intervention. ---
98  2019 Inverse regulation of serum osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand levels in patients with leg lesional vascular calcification: An observational study. ABI, ANOVA, CT scan, OPG, PAD
99  2019 Involvement of p38 Activation and Mitochondria in Death of Human Leukemia Cells Induced by an Agonistic Human Monoclonal Antibody Fab Specific to TRAIL Receptor 1. ---
100  2019 Involvement of Up-regulation of Death Receptors and Bim in Hispolon-mediated TNF-related Apoptosis-inducing Ligand Sensitization in Human Renal Carcinoma. ---